GRAL
GRAL
NASDAQ · Biotechnology

Grail Inc

$107.97
+27.20 (+33.68%)
As of Sep 21, 9:57 PM ET ·
Financial Highlights (FY 2026)
Revenue
178.86M
Net Income
-496,264,148
Gross Margin
48.5%
Profit Margin
-277.5%
Rev Growth
+38.4%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.5% 48.5% 65.8% 65.8%
Operating Margin -382.0% -343.8% 9.2% 8.6%
Profit Margin -277.5% -263.6% 7.6% 7.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 178.86M 129.26M 2.02B 1.78B
Gross Profit 86.67M 62.64M 1.33B 1.17B
Operating Income -683,197,907 -444,372,419 184.76M 152.85M
Net Income -496,264,148 -322,785,093 154.03M 135.92M
Gross Margin 48.5% 48.5% 65.8% 65.8%
Operating Margin -382.0% -343.8% 9.2% 8.6%
Profit Margin -277.5% -263.6% 7.6% 7.7%
Rev Growth +38.4% +38.4% +15.5% +5.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.78B 1.62B
Total Equity 1.86B 2.14B
D/E Ratio 0.96 0.76
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -507,899,701 -348,706,161 214.07M 192.49M
Free Cash Flow 137.52M 156.47M